RT Journal Article
T1 Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment
A1 Cordani, Marco
A1 Somoza, Álvaro
AB Despite the extensive genetic and phenotypic variations present in the different tumors, they frequently share common metabolic alterations, such as autophagy. Autophagy is a self-degradative process in response to stresses by which damaged macromolecules and organelles are targeted by autophagic vesicles to lysosomes and then eliminated. It is known that autophagy dysfunctions can promote tumorigenesis and cancer development, but, interestingly, its overstimulation by cytotoxic drugs may also induce cell death and chemosensitivity. For this reason, the possibility to modulate autophagy may represent a valid therapeutic approach to treat different types of cancers and a variety of clinical trials, using autophagy modulators, are currently employed. On the other hand, recent progress in nanotechnology offers plenty of tools to fight cancer with innovative and efficient therapeutic agents by overcoming obstacles usually encountered with traditional drugs. Interestingly, nanomaterials can modulate autophagy and have been exploited as therapeutic agents against cancer. In this article, we summarize the most recent advances in the application of metallic nanostructures as potent modulators of autophagy process through multiple mechanisms, stressing their therapeutic implications in cancer diseases. For this reason, we believe that autophagy modulation with nanoparticle-based strategies would acquire clinical relevance in the near future, as a complementary therapy for the treatment of cancers and other diseases.
PB Springer Nature
YR 2019
FD 2019
LK https://hdl.handle.net/20.500.14352/96817
UL https://hdl.handle.net/20.500.14352/96817
LA eng
NO Cordani, M., Somoza, Á. Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment. Cell. Mol. Life Sci. 76, 1215–1242 (2019). https://doi.org/10.1007/s00018-018-2973-y
NO Asociación Española Contra el Cáncer
NO Comunidad de Madrid
NO Ministerio de Economía y Competitividad (España)
NO European Commission
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 17 may 2025